Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7843526 | 1.00 | PTGS2 (0.78) | PTGS2MAPK14PTGS1TEKALOX5 | |
| SCHEMBL7844066 | 0.88 | PTGS2 (0.59) | PTGS2MAPK14ALOX5 | |
| SCHEMBL7833473 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7844433 | 0.88 | PTGS2 (0.80) | PTGS2MAPK14 | |
| SCHEMBL7841916 | 0.86 | PTGS2 (1.00) | PTGS2MAPK14PTGS1 | |
| SCHEMBL6508524 | 0.86 | PTGS2 (1.00) | PTGS2MAPK14PTGS1 | |
| SCHEMBL6503233 | 0.86 | PTGS2 (0.78) | PTGS2MAPK14PTGS1 | |
| SCHEMBL6282411 | 0.84 | PTGS2 (0.57) | PTGS2MAPK14ALOX5 | |
| SCHEMBL6504016 | 0.83 | MAPK14 (0.81) | PTGS2MAPK14 | |
| SCHEMBL7832730 | 0.83 | PPARD (0.56) | PTGS2MAPK14PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | PTGS2 57/4885MAPK14 50/4885PTGS1 9/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | PTGS2 109/4885MAPK14 29/4885PTGS1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.